Comparative Pharmacology
Head-to-head clinical analysis: UNASYN versus VEETIDS 125.
Peer-Reviewed Evidence
Head-to-head clinical analysis: UNASYN versus VEETIDS 125.
UNASYN vs VEETIDS '125'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ampicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs); sulbactam is a beta-lactamase inhibitor that prevents degradation of ampicillin by beta-lactamases.
VEETIDS '125' (presumed to be a formulation containing penicillin V potassium) inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
3 g (ampicillin 2 g + sulbactam 1 g) IV every 6 hours; total daily dose of sulbactam not to exceed 4 g.
125 mg orally twice daily for 5-10 days.
None Documented
None Documented
Ampicillin: ~1 hour (normal renal function); sulbactam: ~1-1.4 hours (normal renal function); prolonged in renal impairment (ampicillin up to 20 hours, sulbactam up to 10-15 hours in anuria).
2-4 hours in patients with normal renal function (CrCl >80 mL/min); prolonged to 20-40 hours in anuria. Clinical note: dosing interval must be adjusted based on creatinine clearance to avoid accumulation.
Renal: ampicillin (~75-90% unchanged) and sulbactam (~75-85% unchanged); biliary/fecal: minimal (<5% for each component).
Primarily renal (80-90% unchanged) via glomerular filtration and tubular secretion; biliary/fecal <5%.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic